Telesis Bio Dividends and Buybacks
Dividend criteria checks 0/6
Telesis Bio does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-4.2%
Buyback Yield
Total Shareholder Yield | -4.2% |
Future Dividend Yield | n/a |
Dividend Growth | n/a |
Next dividend pay date | n/a |
Ex dividend date | n/a |
Dividend per share | n/a |
Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
The Market Lifts Telesis Bio, Inc. (NASDAQ:TBIO) Shares 38% But It Can Do More
Apr 17Codex DNA GAAP EPS of -$0.50, revenue of $5.7M; raises FY22 guidance
Aug 09Codex DNA, Inc. (NASDAQ:DNAY) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 25Pfizer's Codex DNA Deal Hints At Lucrative Pivot To mRNA - Keep An Eye On This Space
Jan 06Codex: Synthetic DNA/mRNA Instrument Developer Holds Impressive Upside In 2021
Sep 24Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if TBIO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TBIO's dividend payments have been increasing.
Dividend Yield vs Market
Telesis Bio Dividend Yield vs Market |
---|
Segment | Dividend Yield |
---|---|
Company (TBIO) | n/a |
Market Bottom 25% (US) | 1.4% |
Market Top 25% (US) | 4.5% |
Industry Average (Life Sciences) | 0.5% |
Analyst forecast (TBIO) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate TBIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TBIO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate TBIO's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as TBIO has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/23 12:28 |
End of Day Share Price | 2024/12/23 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Telesis Bio, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Brandon Couillard | Jefferies LLC |
Paul Knight | KeyBanc Capital Markets Inc. |
Douglas Schenkel | TD Cowen |